Semaglutide for Alcohol Use Disorder

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 2, 2022

Primary Completion Date

April 12, 2024

Study Completion Date

April 19, 2024

Conditions

Alcohol Use DisorderCigarette Smoking

Interventions

DRUG

Semaglutide

Semaglutide (subcutaneous)

DRUG

Sham/placebo

Sham subcutaneous injection

Trial Locations (1)

UNC-Chapel Hill, Chapel Hill

All Listed Sponsors

collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

University of North Carolina, Chapel Hill

OTHER